149 0 Kommentare Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7^th International Neoantigen Summit held in Amsterdam, Netherlands from April 29 - May 1, 2024.

The presentation with the title “KRAS Mutation-Specific TCR-T Cells are Empowered for Improved Multi-Functionality & Durability by Inclusion of a Costimulatory Switch Protein” is available on Medigene’s website: https://medigene.com/science/abstracts/

Overcoming the immunosuppressive solid tumor microenvironment (TME) stands as a major hurdle for durable TCR-T therapies in patients. The PD-1/PD-L1 axis suppresses T cell activation, proliferation, survival, cytokine secretion and cytotoxicity in a TME with tumor cells that express PD-L1. The Company´s PD1-41BB CSP effectively counters this tumor self-defense mechanism against T cell attack by replacing the inhibitory signaling domain of PD-1 expressed by TCR-T cells with the activating signaling domain of 4-1BB, thereby improving TCR-T cell functionality.

Lesen Sie auch

Ihre wichtigsten Termine

Alle Analysten-Augen auf: Biontech, Boeing, Zalando, Fresenius und Hensoldt AG

heute 04:30

Shortseller bluten

Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein!

14.05.24, 12:52

Wendepunkt für die Aktie?

Novavax: Multimilliarden-Dollar-Deal mit Sanofi – Aktie verdoppelt sich!

10.05.24, 11:08

Aktie im Abwärtstrend

Evotec: Gelingt der Turnaround?

09.05.24, 08:33

“Our PD1-41BB CSP, a proprietary component of our End-to-End (E2E) Platform, provides an innovative technology that can be paired with diverse optimal affinity 3S-TCRs that target cancer-testis antigens or neoantigens generated using our high-throughput TCR discovery process,” said Dr. Selwyn Ho, Chief Executive Officer at Medigene. “Extensive in vitro assessments underscore the significant advantages of armoring and enhancing 3S-TCRs with our PD1-41BB CSP, showcasing the potential to surmount the immunosuppressive TME of solid tumors. This breakthrough combination promises enhanced and persistent efficacy of TCR-T therapies in difficult-to-treat solid tumors. The PD1-41BB CSP can be used not only to improve TCR-T therapies but also holds potential to improve functions in other cell types as well as for application in chimeric antigen receptor T cell therapies.”

Seite 1 von 4

Seite 2 ►